Covid-19 roundup: Regeneron scores $2.6B US supply deal for antibody cocktail; Brazilian researchers walk back efficacy rate for Sinovac's candidate
The US is continuing to buy up every dose of antibody cocktail that Regeneron can produce, signing off on a $2.625 billion deal to follow …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
